Literature DB >> 12381537

Pheochromocytoma: an approach to antihypertensive management.

Emmanuel L Bravo1.   

Abstract

Pheochromocytoma and paragangliomas are rare tumors of chromaffin tissue that secrete catecholamines either intermittently or continuously, producing hypertension with a constellation of symptoms and signs that can be frightening to the patient and that continue to provide perplexing problems for clinicians. With surgical treatment, symptoms will be relieved and hypertension normalized or ameliorated for patients who do not have malignant tumors. Appropriate antihypertensive drugs are used to manage hypertension, to control associated cardiovascular symptoms, and to prepare patients for operation. The question debated most often regarding medical therapy of pheochromocytoma is whether antihypertensive treatment regimens other than nonspecific alpha-blockade are just as effective and safe. Understanding the pathophysiologic mechanisms that sustain the hypertension and the pharmacology of antihypertensive agents allows better selection of antihypertensive therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12381537     DOI: 10.1111/j.1749-6632.2002.tb04408.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  12 in total

1.  Rapid progression of skin sclerosis precipitated by a pheochromocytoma in a patient with systemic sclerosis.

Authors:  Jongtaek Lee; Yunsuek Kim; Yoonmi Jin; Hyun-Sook Kim
Journal:  Singapore Med J       Date:  2019-08       Impact factor: 1.858

2.  Dexmedetomidine and remifentanil in the perioperative management of an adolescent undergoing resection of pheochromocytoma -A case report-.

Authors:  Jae-Wook Jung; Jung Kyu Park; Sang Yoon Jeon; Yong Han Kim; So-Hyun Nam; Young-Gyun Choi; Si Ra Bang
Journal:  Korean J Anesthesiol       Date:  2012-12-14

Review 3.  Pheochromocytoma and paraganglioma-an update on diagnosis, evaluation, and management.

Authors:  Amrish Jain; Rossana Baracco; Gaurav Kapur
Journal:  Pediatr Nephrol       Date:  2019-01-02       Impact factor: 3.714

Review 4.  Hypertension and adrenal disorders.

Authors:  Wassim Chemaitilly; Robert C Wilson; Maria I New
Journal:  Curr Hypertens Rep       Date:  2003-12       Impact factor: 5.369

5.  Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome.

Authors:  Susannah Cleary; Jacqueline K Phillips; Thanh-Truc Huynh; Karel Pacak; Abdel G Elkahloun; Jennifer Barb; Robert A Worrell; David S Goldstein; Graeme Eisenhofer
Journal:  J Endocrinol       Date:  2007-05       Impact factor: 4.286

Review 6.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 7.  Adrenal causes of hypertension: pheochromocytoma and primary aldosteronism.

Authors:  William F Young
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

8.  Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?

Authors:  Ryan J Ellis; Dhaval Patel; Tamara Prodanov; Samira Sadowski; Naris Nilubol; Karen Adams; Seth M Steinberg; Karel Pacak; Electron Kebebew
Journal:  J Am Coll Surg       Date:  2013-07-25       Impact factor: 6.113

Review 9.  Anti-hypertensive treatment in pheochromocytoma and paraganglioma: current management and therapeutic features.

Authors:  Alberto Mazza; Michela Armigliato; Maria Cristina Marzola; Laura Schiavon; Domenico Montemurro; Giorgio Vescovo; Marco Zuin; Sotirios Chondrogiannis; Roberta Ravenni; Giuseppe Opocher; Patrick M Colletti; Domenico Rubello
Journal:  Endocrine       Date:  2013-07-02       Impact factor: 3.633

Review 10.  Pheochromocytoma, thyroid disease, and hyperparathyroidism.

Authors:  Emanuel L Bravo
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-03       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.